Aug 0 1 2007

Response to Office Action Summary
Application No. 10/686,262

Applicant: Savva, Michalakis

Examiner: Gollamudi S. Kishore, Ph.D.

1. Claim 1 was amended appropriately to claim the only cationic lipids with carbamate linkages depicted in Formula S and the synthesis of which was demonstrated in multiple

examples.


2. Claim 2 was cancelled and other dependent claims were added.

3-4. The instant cationic compounds disclosed in US patent, 6,268,516 by Schneider et al., distinctly different from the compounds claimed in the pending application 10/686,262. More specifically, all compounds disclosed herein are 1,2-diaminopropyl-3-carbamoyl derivatives whereas the compounds described in US6,268,516 are 1,3-diaminopropyl-2-carbamoyl analogs.

5. Similarly, to the argument above, the compounds claimed in pending application No. 10/686,262 are 1,2-diaminopropyl-3-carbamoyl derivatives whereas the compounds described in copending application 10/686,374 are 1,3-diaminopropyl-2-carbamoyl analogs. Thus, there is no issue of double patenting.

B. Amendments to the Claims

1. (Currently Amended) Cationic lipids of the general formula S for nucleic acid delivery in vitro and in vivo.



$$R_1$$
 R_2
 R_3
 R_4
 R_3

Structure S of cationic lipids for claim 1.

 $R = C_{11}H_{23}, C_{13}H_{27}, C_{15}H_{31}, C_{17}H_{35}, C_{17}H_{31}$

R₁= H, CH₃, CH₂CH₂NH₂, CH₂CH₂NHCH₃, CH₂CH₂N(CH₃)₂, CH₂CH₂NH-C(NH₂)=NH

 R_2 = H, CH_3

 R_3 = H, CH_3

 $R_4=H, CH_3$

The connector shows how the two parts of structure S can be chemically linked together.

- 2. (Cancelled)
- 3. (New) The lipid dispersion of claim 1, comprising an acid salt of the cationic lipids of formula S.
- 4. (New) The lipid dispersion of claim 1, wherein the dispersion further comprises a neutral phospholipid species.
- 5. (New) The lipid dispersion of claim 1, wherein the dispersion further comprises a neutral cholesterol-based surfactant.
- 6. (New) The lipid dispersion of claim 1, further comprising polyethylene glycol moieties.